In addition, we suggested evidence that sensitivity of paclitaxel resistant breast cancer cells to this combination treatment correlates with EMT process by blocking HIF-1α, vimentin, Snali, and Slug and by activating E-cadherin in paclitaxel resistant breast cancer cells. Here, VIM is linked to breast carcinoma.